# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cantor Fitzgerald analyst Olivia Brayer reiterates Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Overweight and maintains $10...
Cantor Fitzgerald analyst Olivia Brayer reiterates Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Overweight and maintains $10...
HC Wainwright & Co. analyst Ed Arce reiterates Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Buy and maintains $13 price ...
Aurinia Pharmaceuticals (NASDAQ:AUPH) reported quarterly earnings of $0.01 per share which met the analyst consensus estimate. ...
- Reuters
The Company recommends that shareholders review the recent report from proxy advisor Glass Lewis, which recommends shareholders...